SCYXSCYNEXIS, Inc.

$38M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$736,000-99.4% YoY

Gross Profit

$736,000100.0% margin

Operating Income

-$9M-1255.0% margin

Net Income

-$14M-1964.4% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

-46.4%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$759,000

Balance Sheet

Total Assets

$108M

Total Liabilities

$47M

Stockholders' Equity

$60M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$736,000	$131M	-99.4%
Gross Profit	$736,000	$131M	-99.4%
Operating Income	-$9M	$117M	-107.9%
Net Income	-$14M	$122M	-111.8%

Revenue Segments

License and Service

$736,000100%

SCYX Q2 2024 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena